Zachary Klaassen speaks with Steven Finkelstein about the FDA approval of Pluvicto™ (177Lu-PSMA-617) in the pre-chemotherapy setting for metastatic castration-resistant prostate cancer. Dr. Finkelstein discusses his team’s achievement of treating the first U.S. patient under this new indication just six days after the March 28, 2025 approval. He highlights results from the PSMAfore trial showing Pluvicto™ reduced progression or death risk by 59% compared to changing ARPI therapy, more than doubling median radiographic progression-free survival from 5.6 to 11.6 months.
Dr. Finkelstein predicts this approval will create a “tidal wave” of radioligand therapy moving upstream before chemotherapy, potentially tripling the eligible patient population. He emphasizes the favorable safety profile with predominantly grade 1-2 side effects and the significance of offering effective therapies earlier, as approximately half of mCRPC patients don’t live long enough to receive second-line treatments.
Dr. Finkelstein was also featured on NewsChannel 9, Syracuse NY, by Kendra Broddus.
Read article here.
Learn more about Radiation Oncology at Associated Medical Professionals (A.M.P.)
